{"id":"https://openalex.org/W2071430187","doi":"https://doi.org/10.2165/11634360-000000000-00000","title":"Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients: A Summary and Method Analysis of Bridging Research in Support of Phase II Dose Selection","display_name":"Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients: A Summary and Method Analysis of Bridging Research in Support of Phase II Dose Selection","alternate_titles":[],"publication_year":2012,"publication_date":"2012-09-01","ids":{"openalex":"https://openalex.org/W2071430187","doi":"https://doi.org/10.2165/11634360-000000000-00000","mag":"2071430187","pmid":"https://pubmed.ncbi.nlm.nih.gov/22852579","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3585695"},"language":"en","primary_location":{"id":"doi:10.2165/11634360-000000000-00000","doi":"https://doi.org/10.2165/11634360-000000000-00000","is_oa":true,"landing_page_url":"https://doi.org/10.2165/11634360-000000000-00000","pdf_url":"https://link.springer.com/content/pdf/10.2165/11634360-000000000-00000.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&amp;D","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2071430187"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.2165/11634360-000000000-00000.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025495039","display_name":"Kari R. Nations","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kari R. Nations","raw_affiliation_strings":["Department of Psychology, College of Liberal Arts, University of Texas at Austin, 1 University Station A8000, Austin, Texas, TX 78712, USA","Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychology, College of Liberal Arts, University of Texas at Austin, 1 University Station A8000, Austin, Texas, TX 78712, USA","institution_ids":["https://openalex.org/I86519309"]},{"raw_affiliation_string":"Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018848503","display_name":"Roberta Bursi","orcid":"https://orcid.org/0000-0001-9118-3786","observed_orcids":["https://orcid.org/0000-0001-9118-3786"]},"institutions":[{"id":"https://openalex.org/I4210162999","display_name":"MSD (Netherlands)","ror":"https://ror.org/05y28vr04","country_code":"NL","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210162999"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Roberta Bursi","raw_affiliation_strings":["Merck Sharp & Dohme Oss BV, Oss, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme Oss BV, Oss, the Netherlands","institution_ids":["https://openalex.org/I4210162999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065632651","display_name":"Peter Dogterom","orcid":"https://orcid.org/0000-0001-8447-2934","observed_orcids":["https://orcid.org/0000-0001-8447-2934"]},"institutions":[{"id":"https://openalex.org/I4210162999","display_name":"MSD (Netherlands)","ror":"https://ror.org/05y28vr04","country_code":"NL","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210162999"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Dogterom","raw_affiliation_strings":["Merck Sharp & Dohme Oss BV, Oss, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme Oss BV, Oss, the Netherlands","institution_ids":["https://openalex.org/I4210162999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009531510","display_name":"Larry Ereshefsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]},{"id":"https://openalex.org/I170528797","display_name":"PAREXEL International (United Kingdom)","ror":"https://ror.org/03rrqwf50","country_code":"GB","type":"company","lineage":["https://openalex.org/I170528797","https://openalex.org/I4210124468"]},{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Larry Ereshefsky","raw_affiliation_strings":["California Clinical Trials Medical Group, Inc., Parexel International, Glendale, California, USA","University of Texas Health Science Center, San Antonio, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"California Clinical Trials Medical Group, Inc., Parexel International, Glendale, California, USA","institution_ids":["https://openalex.org/I170528797","https://openalex.org/I4210124468"]},{"raw_affiliation_string":"University of Texas Health Science Center, San Antonio, Texas, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077619930","display_name":"Lev Gertsik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170528797","display_name":"PAREXEL International (United Kingdom)","ror":"https://ror.org/03rrqwf50","country_code":"GB","type":"company","lineage":["https://openalex.org/I170528797","https://openalex.org/I4210124468"]},{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lev Gertsik","raw_affiliation_strings":["California Clinical Trials Medical Group, Inc., Parexel International, Glendale, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"California Clinical Trials Medical Group, Inc., Parexel International, Glendale, California, USA","institution_ids":["https://openalex.org/I170528797","https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046991927","display_name":"Tim Mant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tim Mant","raw_affiliation_strings":["Quintiles Drug Research Unit at Guy\u2019s Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quintiles Drug Research Unit at Guy\u2019s Hospital, London, UK","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I28927889"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023676126","display_name":"Jacques Schipper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162999","display_name":"MSD (Netherlands)","ror":"https://ror.org/05y28vr04","country_code":"NL","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210162999"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jacques Schipper","raw_affiliation_strings":["Merck Sharp & Dohme Oss BV, Oss, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme Oss BV, Oss, the Netherlands","institution_ids":["https://openalex.org/I4210162999"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5025495039"],"corresponding_institution_ids":["https://openalex.org/I1285764155","https://openalex.org/I86519309"],"apc_list":{"value":3490,"currency":"USD","value_usd":3490},"apc_paid":{"value":3490,"currency":"USD","value_usd":3490},"fwci":2.0793,"has_fulltext":true,"cited_by_count":23,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.84252899,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"12","issue":"3","first_page":"127","last_page":"139"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.013700000010430813,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.010599999688565731,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8679999709129333},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.8949999809265137},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.6230000257492065},{"id":"https://openalex.org/keywords/patient-tolerability","display_name":"patient tolerability","score":0.5910000205039978},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8199999928474426},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6740000247955322},{"id":"https://openalex.org/keywords/glutamatergic-neurotransmission","display_name":"glutamatergic neurotransmission","score":0.8479999899864197}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9389045238494873},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6069546937942505},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5435454845428467},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5413370728492737},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5221524238586426},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43537211418151855},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.4219732880592346},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40543103218078613},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35772156715393066},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018091","descriptor_name":"Receptors, AMPA","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018350","descriptor_name":"alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018350","descriptor_name":"alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018350","descriptor_name":"alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D018350","descriptor_name":"alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018350","descriptor_name":"alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.2165/11634360-000000000-00000","doi":"https://doi.org/10.2165/11634360-000000000-00000","is_oa":true,"landing_page_url":"https://doi.org/10.2165/11634360-000000000-00000","pdf_url":"https://link.springer.com/content/pdf/10.2165/11634360-000000000-00000.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&amp;D","raw_type":"journal-article"},{"id":"doi:10.1007/bf03262197","doi":"https://doi.org/10.1007/bf03262197","is_oa":true,"landing_page_url":"https://doi.org/10.1007/bf03262197","pdf_url":null,"source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&amp;D","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2588041","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3585695","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3585695","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3585695/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs R D","raw_type":"Text"},{"id":"pmid:22852579","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22852579","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.2165/11634360-000000000-00000","doi":"https://doi.org/10.2165/11634360-000000000-00000","is_oa":true,"landing_page_url":"https://doi.org/10.2165/11634360-000000000-00000","pdf_url":"https://link.springer.com/content/pdf/10.2165/11634360-000000000-00000.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&amp;D","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2071430187.pdf","grobid_xml":"https://content.openalex.org/works/W2071430187.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1780394705","https://openalex.org/W1894669387","https://openalex.org/W1970133878","https://openalex.org/W1980049394","https://openalex.org/W1980872763","https://openalex.org/W1990964050","https://openalex.org/W1997808826","https://openalex.org/W2003556240","https://openalex.org/W2004305668","https://openalex.org/W2004930774","https://openalex.org/W2008565079","https://openalex.org/W2020118281","https://openalex.org/W2022279290","https://openalex.org/W2022403517","https://openalex.org/W2024278554","https://openalex.org/W2025005051","https://openalex.org/W2033723429","https://openalex.org/W2038610991","https://openalex.org/W2042166364","https://openalex.org/W2042549454","https://openalex.org/W2045122066","https://openalex.org/W2047273226","https://openalex.org/W2050493044","https://openalex.org/W2057887105","https://openalex.org/W2058128885","https://openalex.org/W2065521724","https://openalex.org/W2067529879","https://openalex.org/W2068981794","https://openalex.org/W2087684961","https://openalex.org/W2097152162","https://openalex.org/W2119414825","https://openalex.org/W2323070599","https://openalex.org/W2399594908","https://openalex.org/W2410753988","https://openalex.org/W2496521435"],"related_works":["https://openalex.org/W7096376593","https://openalex.org/W2042166364","https://openalex.org/W4313201328","https://openalex.org/W2069737877","https://openalex.org/W4402678098","https://openalex.org/W7161982905","https://openalex.org/W4415246252","https://openalex.org/W2007323411","https://openalex.org/W1979361025","https://openalex.org/W4407008298"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1],"key":[2],"challenge":[3,83],"to":[4,38,95,119,142,203,211],"dose":[5,229,283],"selection":[6,284],"in":[7,41,90,130,148,151,196,231,242,280],"early":[8],"central":[9],"nervous":[10],"system":[11],"(CNS)":[12],"clinical":[13],"drug":[14],"development":[15,76],"is":[16,102],"that":[17,60,111],"patient":[18,52,154],"tolerability":[19,47,89],"profiles":[20],"often":[21],"differ":[22],"from":[23,49,264],"those":[24],"of":[25,276],"healthy":[26],"volunteers":[27],"(HVs),":[28],"yet":[29],"HVs":[30,149,179,200],"are":[31,61,285,288],"the":[32,50,75,91,152,226,239],"modal":[33],"population":[34,93],"for":[35,71,125,201,209],"determining":[36],"doses":[37,59],"be":[39],"investigated":[40],"phase":[42,126,137,281],"II":[43,127,282],"trials.":[44,98],"Without":[45],"clear":[46],"data":[48,263,292],"target":[51,92,153],"population,":[53],"first":[54],"efficacy":[55,128],"trials":[56,80,129,139,158],"may":[57],"include":[58],"either":[62],"too":[63,66],"high":[64],"or":[65],"low,":[67],"creating":[68],"undue":[69],"risk":[70],"study":[72,289],"participants":[73],"and":[74,88,146,150,161,164,183,206,216,261,291],"program":[77],"overall.":[78],"Bridging":[79],"address":[81],"this":[82],"by":[84,113],"carefully":[85],"investigating":[86],"safety":[87,247],"prior":[94],"full-scale":[96],"proof-of-concept":[97],"OBJECTIVE:":[99],"Org":[100,251],"26576":[101,252],"an":[103,197],"alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic":[104],"acid":[105],"(AMPA)":[106],"receptor":[107],"positive":[108],"allosteric":[109],"modulator":[110],"acts":[112],"modulating":[114],"ionotropic":[115],"AMPA-type":[116],"glutamate":[117],"receptors":[118],"enhance":[120],"glutamatergic":[121],"neurotransmission.":[122],"In":[123],"preparation":[124],"major":[131],"depressive":[132],"disorder":[133],"(MDD),":[134],"two":[135,265],"separate":[136],"I":[138],"were":[140,159,190,218,253],"conducted":[141],"evaluate":[143],"safety,":[144,259],"tolerability,":[145,215,260],"pharmacokinetics":[147,217],"population.":[155],"METHODS:":[156],"Both":[157],"randomized":[160],"placebo":[162],"controlled,":[163],"included":[165],"multiple":[166],"rising-dose":[167],"cohorts":[168],"(HV":[169],"range":[170,175],"100-400":[171],"mg":[172,177,236],"bid;":[173],"MDD":[174,186,207],"100-600":[176],"bid).":[178],"(n":[180,187],"=":[181,188],"36)":[182],"patients":[184,208,233],"with":[185,250],"54)":[189],"dosed":[191],"under":[192,269],"similarly":[193],"controlled":[194],"conditions":[195],"inpatient":[198],"facility,":[199],"up":[202,210],"14":[204],"days":[205],"28":[212],"days.":[213],"Safety,":[214],"assessed":[219],"frequently.":[220],"RESULTS:":[221],"Despite":[222],"comparable":[223],"pharmacokinetic":[224,262],"profiles,":[225],"maximum":[227],"tolerated":[228],"(MTD)":[230],"depressed":[232],"was":[234],"450":[235],"bid,":[237],"twice":[238],"MTD":[240],"established":[241],"HVs.":[243],"No":[244],"clinically":[245],"relevant":[246],"issues":[248],"associated":[249],"noted.":[254],"CONCLUSION:":[255],"This":[256],"article":[257],"presents":[258],"different":[266],"populations":[267],"examined":[268],"similar":[270],"dosing":[271],"conditions.":[272],"The":[273],"important":[274],"implications":[275],"such":[277],"bridging":[278],"work":[279],"discussed,":[286],"as":[287],"design":[290],"interpretation":[293],"challenges.":[294]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2071430187","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
